PathGroup Launches New SmartGenomics Cancer-Specific Testing

BRENTWOOD, Tenn.--(BUSINESS WIRE)--PathGroup, one of the largest private providers of pathology services in the United States, announced today the launch of new cancer-specific SmartGenomics™ testing, expanding their genomic profiling menu for community-based oncologists. The addition of five diagnostic panels targeting cancers of lung, colon, brain, thyroid and melanoma/GIST represent testing options for newly diagnosed patients, the result of which will enable physicians to make more precise therapeutic recommendations and clinical management decisions.

Help employers find you! Check out all the jobs and post your resume.